{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:23:37Z","timestamp":1787840617631,"version":"build-2784847793"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Inflammatory bowel disease (IBD) is a serious public health problem worldwide. The existing therapy options for IBD are limited and can cause severe difficulties, and thus require more research on alternative therapeutic techniques. Pramipexole is a dopamine receptor agonist with anti-inflammatory effects that was recently discovered. Given the importance of dopaminergic pathways in ulcerative colitis inflammation, we tested pramipexole\u2019s efficacy in a rat colitis model in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Colitis was induced by administering 3% acetic acid intrarectally. Rats were randomly assigned to one of six groups: normal, colitis control, dexamethasone (1 mg\/kg; i.p.), and pramipexole (0.25, 0.5, and 1 mg\/kg; i.p.). In intestinal samples, macroscopic and microscopic lesion ratings, pro-inflammatory cytokine levels (tumor necrosis factor alpha, interleukin-6, and interleukin-1 beta), and myeloperoxidase (MPO) activity were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Compared to the colitis control group, pramipexole (0.5 and 1 mg\/kg) substantially reduced macroscopic and microscopic intestinal damage, pro-inflammatory cytokine levels, and MPO activity. Furthermore, the indices mentioned above were considerably lower in the dexamethasone treatment group compared to the colitis control group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our findings indicate that pramipexole has favorable benefits in treating experimental colitis; however, further research is required to determine its clinical value as an IBD therapeutic agent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/abr.abr_606_24","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:00:10Z","timestamp":1756378810000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Pramipexole Exerts Beneficial Effects in a Rat Model of Acetic Acid-Induced Colitis via Modulating Inflammation"],"prefix":"10.4103","volume":"14","author":[{"given":"Azadeh","family":"Motavallian","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foad","family":"Ghazizadeh","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareh Pastaki","family":"Khoshbin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paridokht","family":"Karimian","sequence":"additional","affiliation":[{"name":"Department of Pathology and Histology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forough","family":"Aghajani Torshkooh","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8]]},"reference":[{"key":"R1-20250829","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.phrs.2014.12.001","article-title":"GABA and GABA receptors in the gastrointestinal tract: From motility to inflammation","volume":"93","author":"Auteri","year":"2015","journal-title":"Pharmacol Res"},{"key":"R2-20250829","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","article-title":"Epidemiology and risk factors for IBD","volume":"12","author":"Ananthakrishnan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R3-20250829","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jaut.2017.07.004","article-title":"Novel therapeutic targets for inflammatory bowel disease","volume":"85","author":"Argollo","year":"2017","journal-title":"J Autoimmun"},{"key":"R4-20250829","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s11481-017-9749-2","article-title":"Dopaminergic regulation of innate immunity: A review","volume":"12","author":"Pinoli","year":"2017","journal-title":"J Neuroimmune Pharmacol"},{"key":"R5-20250829","first-page":"159","article-title":"Validation and optimization of experimental colitis induction in rats using 2, 4, 6-trinitrobenzene sulfonic acid","volume":"7","author":"Motavallian-Naeini","year":"2012","journal-title":"Res Pharm Sci"},{"key":"R6-20250829","doi-asserted-by":"crossref","first-page":"765474","DOI":"10.3389\/fmed.2021.765474","article-title":"Treatment of inflammatory bowel disease: A comprehensive review","volume":"8","author":"Cai","year":"2021","journal-title":"Front Med"},{"key":"R7-20250829","doi-asserted-by":"crossref","first-page":"349","DOI":"10.14336\/AD.2015.0330","article-title":"Dopamine receptors and neurodegeneration","volume":"6","author":"Rangel-Barajas","year":"2015","journal-title":"Aging Dis"},{"key":"R8-20250829","doi-asserted-by":"crossref","first-page":"C393","DOI":"10.1152\/ajpcell.00261.2017","article-title":"Dopamine promotes colonic mucus secretion through dopamine D5 receptor in rats","volume":"316","author":"Li","year":"2019","journal-title":"Am J Physiol Cell Physiol"},{"key":"R9-20250829","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1096\/fj.04-1652fje","article-title":"Dopaminergic regulation of immune cells via D3 dopamine receptor: A pathway mediated by activated T cells","volume":"18","author":"Ilani","year":"2004","journal-title":"FASEB J"},{"key":"R10-20250829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/cc2879","article-title":"Clinical review: Immunomodulatory effects of dopamine in general inflammation","volume":"8","author":"Ch Beck","year":"2004","journal-title":"Crit Care"},{"key":"R11-20250829","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2567.2009.03225.x","article-title":"Inflammation in neurodegenerative diseases","volume":"129","author":"Amor","year":"2010","journal-title":"Immunol"},{"key":"R12-20250829","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaut.2006.07.006","article-title":"Schizophrenia, autoimmunity and immune system dysregulation: A comprehensive model updated and revisited","volume":"27","author":"Strous","year":"2006","journal-title":"J Autoimmun"},{"key":"R13-20250829","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1007\/s10620-015-3698-5","article-title":"Role of dopamine and D2 dopamine receptor in the pathogenesis of inflammatory bowel disease","volume":"60","author":"Tolstanova","year":"2015","journal-title":"Dig Dis Sci"},{"key":"R14-20250829","doi-asserted-by":"crossref","first-page":"39","DOI":"10.17721\/2616_6410.2017.22.39-43","article-title":"The role of central and peripheral D2R receptors in the mechanisms of colonic vascular permealibity during experimental colitis in rats","author":"Prysiazhniuk","year":"2017","journal-title":"Bulletin of Taras Shevchenko National University of Kyiv Series Problems of Physiological Functions Regulation"},{"key":"R15-20250829","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-201X.2004.01260.x","article-title":"Decreased availability of intestinal dopamine in transmural colitis may relate to inhibitory effects of interferon\u2010\u03b3 upon L\u2010DOPA uptake","volume":"180","author":"Magro","year":"2004","journal-title":"Acta Physiol Scand"},{"key":"R16-20250829","doi-asserted-by":"crossref","first-page":"S331","DOI":"10.3233\/JPD-191729","article-title":"Inflammatory bowel diseases and Parkinson\u2019s disease","volume":"9","author":"Brudek","year":"2019","journal-title":"J Parkinson Dis"},{"key":"R17-20250829","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/BF01537589","article-title":"Dopamine in gastrointestinal disease","volume":"35","author":"Glavin","year":"1990","journal-title":"Dig Dis Sci"},{"key":"R18-20250829","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0014-2999(88)90253-1","article-title":"The influence of dopamine agonists and antagonists on indomethacin lesions in stomach and small intestine in rats","volume":"158","author":"Sikiri\u0107","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"R19-20250829","first-page":"141","article-title":"Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson\u2019s disease","volume":"21","author":"Piercey","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"R20-20250829","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0022-3565(24)38124-8","article-title":"Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures","volume":"289","author":"Ling","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"R21-20250829","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/08923973.2017.1284230","article-title":"Pramipexole reduces inflammation in the experimental animal models of inflammation","volume":"39","author":"Sadeghi","year":"2017","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"R22-20250829","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1007\/s11033-021-06357-2","article-title":"An investigation of the anti-inflammatory effects of gabapentin on acetic acid-induced colitis in rats","volume":"48","author":"Motavallian","year":"2021","journal-title":"Mol Bio Rep"},{"key":"R23-20250829","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4103\/1735-5362.268199","article-title":"Ameliorative effect of galantamine on acetic acid-induced colitis in rats","volume":"14","author":"Mahdavi","year":"2019","journal-title":"Res Pharm Sci"},{"key":"R24-20250829","first-page":"30","article-title":"Anti-inflammatory effect of ondansetron through 5-HT3 receptors on TNBS-induced colitis in rat","volume":"11","author":"Motavallian-Naeini","year":"2012","journal-title":"EXCLI J"},{"key":"R25-20250829","first-page":"238","article-title":"Clinicopathologic study of dextran sulfate sodium experimental murine colitis","volume":"69","author":"Cooper","year":"1993","journal-title":"Lab Invest"},{"key":"R26-20250829","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2249.1998.00728.x","article-title":"Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines","volume":"114","author":"Dieleman","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"R27-20250829","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/1523-1747.ep12506462","article-title":"Measurement of cutaneous inflammation: Estimation of neutrophil content with an enzyme marker","volume":"78","author":"Bradley","year":"1982","journal-title":"J Invest Dermatol"},{"key":"R28-20250829","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4103\/2277-9175.140666","article-title":"Inflammatory cells\u2019 role in acetic acid-induced colitis","volume":"3","author":"Sanei","year":"2014","journal-title":"Adv Biomed Res"},{"key":"R29-20250829","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4196\/kjpp.2014.18.4.279","article-title":"A review on chemical-induced inflammatory bowel disease models in rodents","volume":"18","author":"Randhawa","year":"2014","journal-title":"Korean J Physiol Pharmacol"},{"key":"R31-20250829","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1365-2885.2001.00343.x","article-title":"Effects of dopaminergic drugs on inflammatory bowel disease induced with 2, 4\u2010dinitrofluorbenzene in BALB\/c mice","volume":"24","author":"Herak\u2010Perkovi\u0107","year":"2001","journal-title":"J Vet Pharmacol Ther"},{"key":"R32-20250829","first-page":"204","article-title":"On the benefits of silymarin in murine colitis by improving balance of destructive cytokines and reduction of toxic stress in the bowel cells","volume":"4","author":"Esmaily","year":"2009","journal-title":"Cent Eur J Biol"},{"key":"R33-20250829","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/003655200750023787","article-title":"The effect of dexamethasone treatment on murine colitis","volume":"35","author":"Van Meeteren","year":"2000","journal-title":"Scand J Gastroenterol"},{"key":"R34-20250829","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.lfs.2007.01.035","article-title":"Blood\u2013brain barrier transport of pramipexole, a dopamine D2 agonist","volume":"80","author":"Okura","year":"2007","journal-title":"Life Sci"}],"container-title":["Advanced Biomedical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_606_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:26:00Z","timestamp":1787837160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_606_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/abr.abr_606_24","relation":{},"ISSN":["2277-9175"],"issn-type":[{"value":"2277-9175","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"2024-11-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}